ESTRO 35 2016 _____________________________________________________________________________________________________ constraints were violated we re-checked correspondence of the structures to the delineation standards of the Lungtech protocol. Association of violations and the prospectively recorded toxicity was evaluated.
Material and Methods:
Patients with stage I NSCLC treated with SABR between January 2014 and August 2015 were included in this single centre cohort study. They were planned using relaxed breathing 4D CT then treated using VMAT. Baseline and dosimetric data was retrospectively collected by a clinical oncologist or physicist from the radiotherapy records. Patients were followed up at 4 weeks then at 3 monthly intervals until 1 year. CT scans were performed 3 and 12 months post radiotherapy. Prospective data collection was performed at follow up visits for clinical outcomes and acute and late normal tissue toxicity (scored using CTCAE v 3.0).
Results
: 28 patients were included in the study with a median follow up of 10.4 months. 19 patients have attended for post radiotherapy CT scans with 84.2% showing radiological response as per RECIST. All patients were assessed for acute toxicity data, 3.5% (1/28) noted grade 2 reaction. Data on late toxicity was available for 19 patients: 26.3% (5/19) experienced grade 2-3, no grade 4 or 5 reactions were recorded. When adjusted for baseline function (late toxicity score minus baseline score) this fell to 15% (3/19). Other than chest wall (CW) tolerances all dosimetry criteria were met. 10.7% of plans exceeded tolerance to 30cc CW (>30/32) with no recorded episodes of ≥grade 2 CW pain in these patients. 71.4% of plans exceeded dose constraint to 0.01cc CW (>37/39) only 5% (1/20) complained of CW pain. Dosimetric analysis for this patient revealed dose to 30cc of CW was 25.8 Gy (<32), dose to 0.01 cc of CW was 59.1 Gy (<39), volume of PTV and CW overlapping was 0.03 cc and % of PTV-CW overlapping was 0.21%.
Conclusion:
We are achieving low rates of moderate or severe toxicity. Despite achieving dose constraints, a small cohort of patients developed toxicity grade 2-3. We hypothesize that these patients could develop radiotherapy toxicity due to other idiosyncratic factors (genetic polymorphisms, microenvironment Purpose or Objective: The aim of this study is to evaluate efficacy and toxicity of stereotactic body radiation therapy in early stage medically inoperable non-small lung cancer.
Material and Methods: Data from patients affected by medically inoperable stage I NSCLC treated with stereotactic body radiation therapy (SBRT) were prospectively recorded. Treatments were planned employing 4D-CT . The prescribed dose was modulated according to location of the lesion and tolerance of the surrounding organs at risk: 54 Gy in 3 fractions for peripheral lesions, 60 Gy in 4 fractions for lesions adjacent to the chest wall, 60 Gy in 8 fractions for central lesions. The primary endpoints were local control and toxicity, secondary endpoint was survival. The follow-up examinations were performed with CT and/or PET-CT at 1, 3, 6, 9 and 12 months after treatment and every 6 months subsequentely. Acute and late side effects were recorded according to RTOG morbidity Scoring Scale.
Results: From 2009 to 2014, 65 patients were treated. Mean patients' age was 74 years (range 62-86). The lesions had a mean maximum diameter of 20 mm (range 10-36). All but seven patients were staged by PET-CT. 83% of cases lung cancer was histologically proven: 34 cases were adenocarcinoma, 15 squamous cell carcinomas, 5 undifferentiated carcinomas. In the last 11 patients biopsy was not performed because of high risk features for complications and/or patient's refusal. In this last group 81% had a positive PET-CT and lesion growth documented at subsequent CT and just two patients had only lesion growth. Lesion's location were as follow: RUL 25/65 (38%), RML 2/65 (3%), RIL 7/65 (11%), LUL 22/65 (34%) and LIL 9/65 (14%). Median follow-up in 61 evaluable patients was 40 months. Five local failure (8%) were recorded at a mean of 11,5 months from the end of treatment (range 5.3-22). PET-CT SUV was the only parameter predictive for local failure, with a mean value of 14,2 in the recurrence group versus 6,1 in the recurrence-free group, respectively; p = 0.03. Local control at 1 and 2 years were 89.6% and 86%. Median DFS was 22.2 months and 1y-, 2y-and 3y-DFS were 66%, 47% and 40%, respectively. Lesions' location according to treatment group was related to distant progression, which was significantly higher in peripheral location (p=0.004). Overall survival at 1y-, 2y-and 3y were 97%, 77% and 66%, respectively. Treatment was well tolerated. G1 asymptomatic pulmonary toxicity was observed in 18% of cases (11/61), G2 pulmonary toxicity was recorded in 3% of patients. There were no pulmonary toxicity grade 3-4. No other toxicities were reported.
SBRT is an effective and safe treatment for patients with medically inoperable stage I NSCLC. Local recurrence predictive value of PET-CT SUV could be investigated in bigger series. 
EP-1243

